These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27067805)

  • 1. New potential binding determinant for hERG channel inhibitors.
    Saxena P; Zangerl-Plessl EM; Linder T; Windisch A; Hohaus A; Timin E; Hering S; Stary-Weinzinger A
    Sci Rep; 2016 Apr; 6():24182. PubMed ID: 27067805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular determinants of hERG channel block by terfenadine and cisapride.
    Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
    J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
    Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
    Siebrands CC; Friederich P
    Anesthesiology; 2007 Mar; 106(3):523-31. PubMed ID: 17325511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular determinants of dofetilide block of HERG K+ channels.
    Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
    Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open channel block of HERG K(+) channels by vesnarinone.
    Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
    Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
    Perry M; Sachse FB; Abbruzzese J; Sanguinetti MC
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20075-80. PubMed ID: 19892732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural implications of hERG K
    Helliwell MV; Zhang Y; El Harchi A; Du C; Hancox JC; Dempsey CE
    J Biol Chem; 2018 May; 293(18):7040-7057. PubMed ID: 29545312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K
    Ma S; Sun Z; Jing Y; McGann M; Vajda S; Enyedy IJ
    Chem Res Toxicol; 2022 Aug; 35(8):1359-1369. PubMed ID: 35895844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A structural basis for drug-induced long QT syndrome.
    Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
    Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain.
    Perissinotti L; Guo J; Kudaibergenova M; Lees-Miller J; Ol'khovich M; Sharapova A; Perlovich GL; Muruve DA; Gerull B; Noskov SY; Duff HJ
    Mol Pharmacol; 2019 Aug; 96(2):259-271. PubMed ID: 31182542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
    Melgari D; Brack KE; Zhang C; Zhang Y; El Harchi A; Mitcheson JS; Dempsey CE; Ng GA; Hancox JC
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25911606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
    Siebrands CC; Schmitt N; Friederich P
    Anesthesiology; 2005 Jul; 103(1):102-12. PubMed ID: 15983462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia.
    Wan H; Selvaggio G; Pearlstein RA
    PLoS One; 2020; 15(11):e0234946. PubMed ID: 33147278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serine mutation of a conserved threonine in the hERG K
    Al-Moubarak E; Zhang Y; Dempsey CE; Zhang H; Harmer SC; Hancox JC
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1085-1091. PubMed ID: 32321643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain.
    Sănchez-Chapula JA; Ferrer T; Navarro-Polanco RA; Sanguinetti MC
    Mol Pharmacol; 2003 May; 63(5):1051-8. PubMed ID: 12695533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
    Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
    Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
    Park SJ; Kim KS; Kim EJ
    J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
    Ridley JM; Milnes JT; Witchel HJ; Hancox JC
    Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.